Jazz FDA OK for Ziihera combo as 1st-line treatment for gastroesophageal adenocarcinoma
Jazz Pharmaceuticals announces U.S. FDA approval of Ziihera (zanidatamab-hrii) combination regimens as first-line treatment for HER2-positive advanced gastroesophageal adenocarcinoma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.